Nuvalent, Inc.
NUVL
Rang in aandelen
#2112
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aandeelprijs
$123.96
Laatst gesynchroniseerd: 2026-07-21
Marktkapitalisatie
$9.75B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
27.56%
Land
US
Handel Nuvalent, Inc. (NUVL)
Categorie
Healthcare
Winst voor Nuvalent, Inc. (NUVL)
Winst in Mar 2026 TTM: $-449.48M
Volgens de meest recente financiële verslagen van Nuvalent, Inc. bedraagt de huidige winst van het bedrijf $-449.48M. In 2023 behaalde het bedrijf een winst van $-126.22M, een daling ten opzichte van de winst van 2022, die $-81.85M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Nuvalent, Inc. van 2019 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-449.48M | 72.88% |
| 2024 | $-259.99M | 105.98% |
| 2023 | $-126.22M | 54.20% |
| 2022 | $-81.85M | 76.65% |
| 2021 | $-46.34M | 218.34% |
| 2020 | $-14.56M | 23.26% |
| 2019 | $-11.81M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -1,273.56% |
US
|
|
| $-3.09B | 586.80% |
US
|
|
| $-4.02B | 793.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -533.98% |
NL
|
